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An Australian patient with autism was found to be
heterozygous for two mutations in the gene encoding
adenylosuccinate lyase (ASL), resulting in the protein
mutations E80D and D87E. The patient’s mother carried
only the E80D mutation. The equivalent positions are 62
and 69 in Bacillus subtilis ASL. Although both human
and B. subtilis enzymes normally have Asp at position 87
(or 69), the B. subtilis ASL has Ile and Asp at 62 and 65,
respectively, whereas human ASL has Glu and Arg at
the equivalent positions. We have constructed, ex-
pressed, and purified the double mutant I62E/D65R as a
“humanized” normal B. subtilis enzyme to compare with
enzymes with a single mutation at position 62 (I62D/
D65R), at position 69 (I62E/D65R/D69E), or at both posi-
tions (I62D/D65R/D69E). Vmax for conversion of adenylo-
succinate to AMP and fumarate is 0.57 mol/min/mg for
I62E/D65R, 0.064 mol/min/mg for I62D/D65R, 0.27 mol/
min/mg for I62E/D65R/D69E, and 0.069 mol/min/mg for
I62D/D65R/D69E. The Km for adenylosuccinate is ele-
vated in the X62D mutants, and I62D/D65R is the least
stable of these ASLs at 37 °C. The CD spectra of mutant
and wild type enzymes are similar; thus, there are no
appreciable structural changes. Clearly the Asp62
causes the most drastic effect on ASL function, whereas
the Glu69 mutation produces only modest change. These
results emphasize the importance of expanding tests for
ASL deficiency to individuals with developmental delay
of any severity, including individuals with autistic spec-
trum disorder. This study further demonstrates the use-
fulness of the B. subtilis ASL as a model to mimic the
defective enzyme in ASL deficiency.
Adenylosuccinate lyase deficiency is an inborn error of me-
tabolism resulting from a defective enzyme important in the de
novo pathway of purine biosynthesis (1, 2). This deficiency is
characterized by variable degrees of developmental delay, often
accompanied by autistic features and epileptic seizures (2).
Biochemically, the enzyme deficiency is diagnosed by the ap-
pearance in cerebrospinal fluid, urine, and to a smaller extent
in plasma, of succinylaminoimidazole carboxamide riboside
(SAICA-riboside)1 and succinyladenosine (S-Ado) (2).
ASL catalyzes two distinct reactions in the synthesis of pu-
rine nucleotides, as shown in Scheme Ia, the cleavage of ad-
enylosuccinate (SAMP) to AMP, the second step in the conver-
sion of IMP to AMP and, Scheme Ib, the conversion of
succinylaminoimidazole carboxamide ribotide (SAICAR) to
aminoimidazole carboxamide ribotide (AICAR), the eighth step
of the de novo synthesis (3). The two reactions proceed by
-elimination of fumarate via a general base-general acid
mechanism, where the general base abstracts a methylene
proton from the carbon in the -position relative to the leaving
nitrogen, and the general acid donates a proton to the leaving
nitrogen. The succinyladenosine and SAICA-riboside detected
in the ASL-deficient patients are the dephosphorylated deriv-
atives of SAMP and SAICAR, respectively. In severely affected
patients, the concentrations of the compounds are comparable,
whereas in more mildly affected patients, the concentration of
SAICA-riboside is in the same range, but the succinyladenosine
concentration is much higher, resulting in S-Ado/SAICA ribo-
side ratios of greater than 2 (2, 4). To date, 60 patients with
ASL deficiency have been diagnosed worldwide, but there may
be many more because there has not been general screening for
this disease, especially in cases of mild developmental delay or
autism.
This study focuses on a recently identified individual from
Australia with ASL deficiency, diagnosed with autism at the
age of 2; it was not until the age of 6 years that he experienced
2 epileptic seizures and was subsequently treated with an
anticonvulsant (5). The patient has elevated levels of S-Ado
and SAICA-riboside in the urine (normally undetectable), con-
sistent with mild ASL deficiency. We report here the identifi-
cation of the mutations in the ASL of this patient. To gain
insight into the effect of these mutations on the catalytic and
structural features of the enzyme, we have introduced these
mutations into the ASL from Bacillus subtilis at the positions
equivalent to those of the human enzyme.
The human gene encoding ASL is located on chromosome
22q13.2. To date, more than 30 different mutations in the ASL
gene causing this deficiency have been identified worldwide.
The mutations resulting in ASL deficiency are located through-
out the enzyme, with the majority of them being relatively far
from the active site. However, biochemical study of the human
ASL has been conducted in only a limited number of cases (7–9)
because of the instability of the enzyme. As an alternative,
because of the high structural similarity between the enzymes
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in this family, we have previously used the more stable
B. subtilis ASL as a model system and have constructed in the
bacterial enzyme other mutations corresponding to those asso-
ciated with human ASL deficiency (10, 11).
ASL is a homotetramer with single chains containing 431–
487 amino acids, depending on the source, with a molecular
mass of 200 kDa. The active site of the ASL of B. subtilis has
been examined by affinity labeling and site-directed mutagen-
esis, implicating in the active site His68 and His141 (12–14),
His89 (15), Lys268 and Glu275 (16), and Gln212, Asn270, and
Arg301 (17). The ASL of Thermotoga maritima has been crys-
tallized, and its coordinates are deposited in the Protein Data
Bank (18). The B. subtilis and T. maritima enzymes share 50%
identity plus 23% similarity in amino acid sequence, whereas
the B. subtilis and human ASL share 25% identity plus 23%
similarity in sequence. Homology models of the B. subtilis (16)
and human enzymes (11) have been constructed based on the
crystal structure of T. maritima ASL. The structural models of
these three enzymes are superimposable (11) and have been
used to relate four human enzyme amino acid residues previ-
ously identified in ASL-deficient patients to B. subtilis amino
acid residues (10, 11). We report here two new disease-associ-
ated mutations and the characterization of mutant enzymes
with substitutions at positions 62 and 69 of the B. subtilis ASL
to provide insight into the effects of the corresponding new
disease-associated mutations found in the human enzymes se-
quenced in this paper. A preliminary version of this work has
been presented (19).
EXPERIMENTAL PROCEDURES
Materials—SAMP, AICAR, HEPES, and imidazole were purchased
from Sigma. Oligonucleotides for both sequencing and site-directed
mutagenesis were obtained from Biosynthesis. The protein assay con-
centrate was from Bio-Rad. All other chemicals were of reagent grade.
Identification of Adenylosuccinate Lyase Deficiency Mutations—PCR-
amplified DNAs corresponding to each exon from the affected individ-
ual and mother were sequenced. The DNA of the father was not avail-
able. Genomic DNA was isolated from whole peripheral blood cells (20).
The exons of ASL were amplified using the PCR primers described in
Kmoch et al. (8), with slight modifications. The PCR products were
either purified using a Roche Applied Science High Pure Purification
kit and sequenced directly or cloned using the Promega pGEM-T Easy
Vector and Novagen NovaBlue competent cells and purified using the
Promega Wizard Plus Minipreps and sequenced using an ABI Big Dye
Terminator Cycle Sequencing kit. Sequences were read on either an
ABI Prism 377 DNA sequencer or an ABI 373 Stretch DNA sequencer.
Site-directed Mutagenesis—Mutations to the pBHis plasmid (a gift
from Dr. Jack E. Dixon, University of Michigan) that encodes adenylo-
succinate lyase of B. subtilis were constructed using the Stratagene
QuikChange mutagenesis kit. The following oligonucleotides and their
complements were used to generate the Ile62 mutant enzymes: CGC
ATT TTA GAA GAA GAA AAG GAC ACG CG (I62E) and C CGC ATT
TTA GAA GAT GAA AAG GAC ACG CG (I62D). The Asp69 mutant
enzyme was generated from the following oligonucleotide and its com-
plement: C ACG CGC CAT GAA GTT GTC GCT TTT AC (D69E). The
Asp65 mutant enzyme D65R was generated from the GAA ATC GAA
AAG CGC ACG CGC CAT GAC G oligonucleotide and its complement.
The I62E/D65R and I62D/D65R mutant enzymes were constructed
using the corresponding Ile62 mutant cDNA as the template and the
following oligonucleotides and their complements: GAA GAA GAA AAG
CGC ACG CGC CAT GAC G (Glu/Arg) and GAA GAT GAA AAG CGC
ACG CGC CAT GAC G (Asp/Arg), respectively. The I62E/D65R/D69E
and I62D/D65R/D69E mutant enzymes were constructed using the
D69E oligonucleotide and its complement on the I62E/D65Rand I62D/D65R
mutant cDNA templates, respectively. The I62E/D69E, I62D/D69E, and
D65R/D69Emutant enzymes were constructed using the D69E oligonucleo-
tide and its complement on the I62E, I62D, and D65R mutant cDNA tem-
plates, respectively. The mutations were confirmed by DNA sequencing,
carried out at the Delaware Biotechnology Institute and University of Del-
aware Center for Agricultural Biotechnology using an ABI Prismmodel 377
DNA sequencer (PE Biosystems).
The pBHis plasmid, which encodes a His6 tag on the N-terminus of
adenylosuccinate lyase, was expressed in Escherichia coli strain BL21
(DE3), and the enzymes were purified to homogeneity using Qiagen
nickel nitrilotriacetic acid-agarose (12, 21). The purity of the enzymes
was evaluated by 12% polyacrylamide gels containing 0.1% sodium
dodecyl sulfate, and the protein concentrations were determined by the
absorbance at 280 nm using E280 nm
1%  10.6 (12). The purified enzyme
was separated into aliquots and stored at 80 °C in 20 mM potassium
phosphate containing 20 mM sodium chloride, pH 7.
SCHEME I
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SAICAR Synthesis—SAICAR was prepared enzymatically from
AICAR (10 mM) and fumarate (100 mM) with adenylosuccinate lyase
(0.4 mg/ml) in 50 mM HEPES, pH 7.0, reaction mixture (2.5-ml total
volume). The reaction was allowed to proceed for 2 h and was monitored
on the UV-visible spectrophotometer (Hewlett Packard 8453) by the
decrease in absorbance of AICAR at 267 nm and increase in absorbance
of SAICAR at 269 nm. The enzyme was removed by filtering the reac-
tion mixture using a Centricon-10 filtration device (Millipore). The
filtrate was then applied to a DEAE-cellulose column (1.5  43 cm)
equilibrated with 10 mM NH4HCO3, pH 7.9, and the compounds were
eluted using a linear gradient from 10 mM (1 liter) to 300 mM (1 liter)
NH4HCO3, pH 7.9. Of the three peaks seen, the first and second peaks
are attributed to the unreacted reagents fumarate and AICAR, respec-
tively. The product SAICAR elutes as the third peak, detected by the
absorbance at 269 nm. The fractions from the third peak were pooled,
evaporated to dryness under vacuum, redissolved in water, and applied
to a Dowex-50 column (24  1 cm) (Bio-Rad A 50W-X4, 100–200 mesh,
hydrogen form) equilibrated with 0.1 M HCl to desalt the product.
SAICAR was eluted using water. The overall yield of the final product
was 32%.
Kinetics of B. subtilis Adenylosuccinate Lyase—The enzymes were
incubated at a minimum concentration of 0.4 mg/ml in 20 mM potas-
sium phosphate containing 20 mM sodium chloride, pH 7.0, for 30 min
at 25 °C before activity measurements. The activity of wild type and
mutant enzymes toward SAMP was measured by the time-dependent
decrease in absorbance at 282 nm using the difference extinction coef-
ficient of 10,000 M1 cm1 (22), whereas the activity toward SAICAR
was tested from the time-dependent increase in absorbance at 267 nm
using the difference extinction coefficient of 700 M1 cm1 (23). Stand-
ard assay conditions of 50 mM HEPES, pH 7.0, at 25 °C with 60 M
SAMP were used for the determination of specific activity, expressed as
the mol of substrate converted/min/mg of enzyme used. For the activ-
ity ratios of SAMP and SAICAR, 90 M concentrations of each substrate
were used to ensure saturating conditions (10). The Km for wild type
and mutant enzymes was determined by varying the substrate con-
centration under the same conditions. The data were analyzed by
Lineweaver-Burk plots with S.E. estimates obtained from the Sig-
maPlot software (SPSS Inc., Chicago, IL).
Circular Dichroism Spectroscopy—The Jasco J-710 spectropolarime-
ter was used to measure ellipticity as a function of wavelength from 250
to 200 nm in 0.2-nm increments using a 0.1-cm cylindrical quartz
cuvette. The wild type and mutant enzymes were incubated at 0.4
mg/ml for 30 min at 25 °C before measuring the spectra, and the final
protein concentration was determined by the Bio-Rad protein assay,
which is based on the method of Bradford, using wild type adenylosuc-
cinate lyase as the protein standard (24). The samples were scanned
five times and averaged, and the spectrum of the buffer, containing 20
mM potassium phosphate and 20 mM sodium chloride at pH 7, was
subtracted. The mean molar ellipticity [] (deg cm2 dmol1) was calcu-
lated from the equation []  /10 nCl, where  is the measured
ellipticity in millidegrees, C is the molar concentration of enzyme sub-
units, l is the path length in centimeters, and n is the number of
residues per subunit (437, including the His6 tag).
Thermal Stability of Wild Type and Mutant Enzymes—The wild type
and mutant enzymes were incubated at 1 mg/ml at 37 °C, and 20–
200-l aliquots were assayed (depending on the activity of the enzyme)
under standard conditions every 10 min for the first hour and every 15
min for the next 3 h. All the enzyme samples were preincubated for 30
min at 25 °C in 20 mM potassium phosphate buffer, pH 7.0, containing
20 mM sodium chloride before being transferred to 37 °C.
Molecular Weight Determination by Light Scattering—The wild type
and mutant enzyme molecular weights were determined using a min-
iDAWN laser photometer (Wyatt Technology Corp., Santa Barbara,
CA). The molecular weights were determined at a protein concentration
of 0.25 mg/ml in 20 mM potassium phosphate containing 20 mM sodium
chloride, pH 7. The protein concentrations were determined by Bio-Rad
protein assays after collecting data. The data were collected at room
temperature at the laser wavelength of 690 nm and analyzed using
ASTRA software for Windows (25).
Molecular Weight Determination of I62E/D65R and I62D/D65R by
Native Gels—The wild type, I62E/D65R, and I62D/D65R mutant en-
zyme molecular weights were determined by native polyacrylamide gel
electrophoresis, as described by Palenchar et al. (11). Using a constant
ratio of acrylamide to bisacrylamide (37.5:1), the gels were prepared
with final concentrations of 5–9% and were run at pH 7.0 in 20 mM
potassium phosphate, pH 7.0, at 25 °C and 25 mA.
Modeling of Human and B. subtilis ASL Based on the Structure of
T. maritima—Homology models of B. subtilis ASL have been con-
structed using as templates the structure of either the T. maritima
enzyme crystallized at pH 4.5 (PDB1c3c) (16) or the structure of the
same enzyme crystallized at pH 9.0 (PDB1c3u) (17). Here we use the
homology models of the B. subtilis and human ASLs based on the native
T. maritima enzyme structure (PDB1c3u), as previously described by
Segall and Colman (17), to study the human mutations identified in the
affected individual. Amino acid substitutions were made for the point
mutations identified in the affected individual, and energy minimiza-
tion measurements were conducted using Discover 3.1 simulation pro-
gram with Insight II molecular software (Biosym).
RESULTS
Identification of Point Mutations in Adenylosuccinate Lyase-
deficient Patient—To determine the mutations present in the
ASL gene of the affected child, PCR amplified genomic DNA
corresponding to each exon from the affected individual and
mother was sequenced. The DNA sequences of the relevant
region from the mother and proband are shown in Fig. 1. Two
mutations were found in the proband, and one in the parent;
both are on exon 2 of the ASL gene. The first mutation is an A
FIG. 1. DNA sequence from mother
and proband in the relevant region.
The trinucleotide regions leading to the
amino acid substitutions E80D and D87E
are boxed, and the mutant nucleotides are
marked by red arrows.
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to C substitution at nucleotide 242 of the coding sequence
leading to a glutamate (GAA) to aspartate (GAC) substitution
at amino acid 80 (E80D). Both the affected individual and the
parent are heterozygous for this mutation. The second muta-
tion is a T to G substitution at nucleotide 263 resulting in an
aspartate (GAT) to glutamate (GAG) substitution at amino acid
position 87 (D87E). The mother has the wild type coding se-
quence for D87, whereas the proband is heterozygous for the
mutation encoding D87E. No other nucleotide changes were
found in the ASL genes of the patient or the mother.
Equivalent Mutations in B. subtilis to the Adenylosuccinate
Lyase Deficiency-associated Mutations Found in Humans—
This study focuses on two point mutations identified in the
child with adenylosuccinate lyase deficiency (5). As shown in
Fig. 2, amino acid residues 80 and 87 in the human sequence
correspond, respectively, to amino acids 62 and 69 of the
B. subtilis enzyme based on sequence alignment generated
using ClustalW. A complete sequence alignment of the adenylo-
succinate lyases from H. sapiens, B. subtilis and T. maritima
was published previously (11). The two point mutations in the
human enzyme are E80D and D87E, and the corresponding
residues in the B. subtilis enzyme are Ile62 and Asp69; thus, the
Asp at position 87 in the normal human enzyme is conserved,
but the Glu at position 80 is not conserved. Therefore, I62E was
constructed to mimic the normal human enzyme at positions 80
and 87, I62D was generated to correspond to the single muta-
tion of the ASL-deficient child at position 80, and D69E was
designed to correspond to the single mutation of the affected
child at position 87.
In addition, we noted that B. subtilis adenylosuccinate lyase
has a negatively charged aspartate at position 65, whereas the
equivalent amino acid in the human enzyme is the positively
charged arginine and the corresponding amino acids in the
T. maritima, mouse and chicken are also positively charged.
Thus, in the B. subtilis enzyme, we replaced the Asp65 with Arg
(D65R). The double mutants I62E/D65R and I62D/D65R were
constructed to better mimic the normal human and ASL-defi-
cient enzyme at position 80 (E80D), respectively.
The I62E/D65R/D69E mutation best mimics the deficient
single point mutation at position 87 in the human (D87E). We
constructed I62D/D65R/D69E to mimic the two point muta-
tions seen in the affected child. The I62E/D69E, I62D/D69E,
D65R/D69E, and D69Emutations were constructed as controls.
The mutant enzymes were expressed in E. coli and purified to
homogeneity. Representative enzyme samples are shown on
the SDS-PAGE gel in Fig. 3.
Kinetics of Mutant Enzymes—All the mutant B. subtilis en-
zymes constructed exhibit sufficient activity to be character-
ized kinetically. The Vmax and Km values using SAMP as sub-
strate are summarized in Table I. The Vmax value of the I62E
mutant enzyme (which was expected to be close to that of the
normal enzyme) is very low when compared with that of the
wild type B. subtilis ASL (lines 1 and 2). In the B. subtilis
enzyme model, the decrease in activity could be due to the
repulsion between the negatively charged group at position 62
and that of the neighboring residue, Asp65. Indeed, low Vmax
values are observed for the enzymes of rows 2, 3, 5 and 6, all of
which have a negatively charged amino acid at position 62.
Therefore, Asp65 was replaced by Arg (D65R); and the D65R
enzyme activity is reasonably close to that of wild type enzyme
(lines 1 and 7). Compared with the activities of the single
mutants (lines 2 and 3), the double mutants (lines 9 and 11),
I62E/D65R and I62D/D65R, exhibit appreciably higher Vmax
values. The original Asp65 residue of the B. subtilis enzyme
apparently does have an unfavorable interaction with the neg-
atively charged amino acid at position 62 in the I62E and I62D
enzymes.
The mutant enzyme of line 9 (with 62E, 65R and 69D) is the
best representation of a normal humanized B. subtilis ASL.
Accordingly, all disease-associated mutations are best com-
pared with the enzyme of line 9 (I62E/D65R). The most inform-
ative mutant enzymes are those shown in lines 9–12: line 10
(as compared with line 9), illustrates the effect of the single
disease-associated mutation at position 69; line 11 represents
the impact of the single disease-associated mutation at position
62; and line 12 illustrates the result of the double defect at both
positions 62 and 69. The single mutation at position 69 causes
only a 2-fold decrease in Vmax (line 10), whereas the single
defect at position 62 results in a 9-fold reduction in Vmax (line
11). The double defect (line 12) is very similar in Vmax to the
I62D/D65R mutant. Therefore, the I62D single point mutation
causes a more significant decrease in the enzyme activity than
does the D69E single point mutation. Because the child is
heterozygous for the mutations, we tested the activity of an
equal mixture of I62D/D65R and I62E/D65R/D69E mutant en-
zymes. This mixture gave a Vmax value of 0.12 mol substrate/
min/mg protein (data not shown), which is almost twice that of
the double mutant (line 12). Table I also reports the kcat values
for wild type and the various mutants.
Compared with the wild type Km of 4 M for adenylosucci-
nate, the humanized normal mutant enzyme (line 9), I62E/
D65R, has a 4-fold higher Km, whereas the I62D change results
in a 14-fold higher Km when present as a single mutation (line
3). This higher Km value is also seen in the humanized I62D/
D65R single 62 mutant (line 11). The double defect mutant has
a Km lower than that of a single I62D mutant (line 12 versus
line 11; line 6 versus line 3). The effect of the single mutation of
D69E is to reduce the Km for adenylosuccinate (line 4 versus
line 1; line 10 versus line 9). Thus it is not surprising that the
Km of the double mutant reflects the favorable contribution of
D69E to the apparent affinity for substrate. The D65R mutant
enzyme has a Km value that is similar to that of the wild type
enzyme (line 7 versus 1). Compared with the catalytic efficiency
FIG. 2. Amino acid sequence alignments of adenylosuccinate
lyase from B. subtilis, human, T. maritima, mouse, and chicken,
according to CLUSTALW.
FIG. 3. SDS-PAGE of representative purified enzymes. The con-
tents of each lane are as follows: lane 1, protein standards; lane 2, WT;
lane 3, I62E; lane 4, I62D; lane 5, D69E; lane 6, I62E/D65R; lane 7,
I62D/D65R; lane 8, I62E/D65R/D69E; lane 9, I62D/D65R/D69E; and
lane 10, I62D/D69E. Approximately 5 g of each sample was applied to
the gel.
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(kcat/Km) of the normal human-like enzyme, the I62D/D65R
mutant enzyme is 25-fold less efficient (line 9 versus 11)
whereas the I62E/D65R/D69E mutant enzyme exhibits a min-
imal change in kcat/Km (line 9 versus 10). Therefore, the Vmax
and Km values of the ASL-deficient mutant enzymes are pre-
dominantly affected by the I62D single point mutation.
SAICAR/SAMP Ratios of Wild Type and ASL Deficiency-
associated Mutant Enzymes—In some patients with ASL defi-
ciency, there is a differential effect on the enzyme’s catalytic
activity toward SAMP and SAICAR (2). The relative activities
toward the 2 substrates are compared in Table II for the mu-
tants constructed in the present study. The activities of the
wild type and all mutant enzymes are similar for the two
substrates tested. The activities of the humanized single defect
mutant at 69 (I62E/D65R/D69E), double defect mutant (I62D/
D65R/D69E) and the heterozygous enzyme mixture (I62D/
D65R  I62E/D65R/D69E) exhibit only a slightly higher
SAICAR/SAMP ratio.
Circular Dichroism Spectroscopy of Wild Type and Mutant
Enzymes—Circular dichroism was used to detect any major
changes in the secondary structure of the mutant enzymes that
might be responsible for the altered catalytic activities. The CD
spectra of all the mutant B. subtilis enzymes are shown in Fig. 4.
The wild-type and the single point mutations equivalent to those
identified in the affected child are shown in Fig. 4A. The human-
ized enzymes with ASL deficiency single defects at 62, 69, and
the double defect (equivalent to lines 9–12, Table I) are shown in
Fig. 4B. The control mutant enzymes for all the ASL deficiency
mutations are shown in Fig. 4C. Wild type and all mutants show
minima in ellipticity at 208 and 222 nm, typical of proteins
containing -helices. Overall, there is no appreciable difference in
the CD spectra of the mutant enzymes.
Molecular Weight Determination of Wild Type and Mutant
Enzymes—To evaluate the effect of the disease-associated mu-
tations on the oligomeric state of the enzyme, light scattering
was used. Because the molecular weights depend on protein
concentration (10), the determinations were made at the same
concentration (0.25 mg/ml), yielding the molecular weights
shown in Table III. The results show that the molecular
weights are consistent with an equilibrium mixture between
the dimeric and tetrameric structure of the wild type and
mutant enzymes, as we have previously demonstrated for wild
type enzyme (10).
Light scattering could not be used on the humanized en-
zymes with single mutations at position 62, I62E/D65R and
I62D/D65R, because of their tendency to aggregate. Therefore,
the molecular weights of these enzymes were determined using
native gel electrophoresis (11), based on the relative mobility
(RM) of the samples in the 5–9% polyacrylamide gels. The
calculated molecular mass of the wild type enzyme is 210 kDa.
The I62E/D65R and I62D/D65R mutant enzymes exhibit dis-
tinct bands of 209 kDa and 217 kDa, respectively, as the small-
est species present; however, they also exhibit an appreciable
amount of higher molecular weight bands of about 381 kDa and
336 kDa, respectively. These results are consistent with the
thermal instability of these mutant enzymes.
Thermal Stability Studies of Wild Type and ASL Deficiency-
associated Human Mutant Enzymes—To evaluate the effect of
the ASL deficiency-associated point mutations on the stability
of the enzyme, the rates of inactivation of wild type and mutant
enzymes were tested at 37 °C, chosen since it is close to the
physiological temperature. The time-dependent inactivations
are illustrated in Fig. 5 and the rate constants are summarized
in Table IV. Of the ASL deficiency-associated point mutations
studied, I62D/D65R is the most unstable enzyme, with a rate
constant for inactivation of 0.025 min1. Neither the wild type
nor the normal humanized enzyme (I62E/D65R) is completely
stable over the time period studied. The ASL deficiency double
mutant (I62D/D65R/D69E) enzyme is the second most unstable
mutant with k 0.012 min1, compared with the wild type and
normal humanized enzymes of 0.003 min1 and 0.009 min1,
respectively. Therefore, the I62D mutation seems to have the
most detrimental effect on the stability of the enzyme.
DISCUSSION
The present study identifies two new point mutations asso-
ciated with adenylosuccinate lyase deficiency found in an af-
fected individual in Australia and characterizes them using the
B. subtilis enzyme as a model. The physical features of the
mutant enzymes did not show an appreciable difference from
wild type enzyme in the secondary and overall enzyme struc-
ture. But there are significant differences in thermal stability,
catalytic activity and substrate binding in these mutant en-
zymes. When compared with the normal human-like enzyme
(I62E/D65R), the single mutant at position 69 (I62E/D65R/
D69E) causes only a 2-fold decrease in Vmax, whereas a single
defect at 62 (I62D/D65R) results in a 9-fold reduction in Vmax.
The double defect (I62D/D65R/D69E) mutant is very similar in
Vmax to the X62D mutant. An equal mixture of the two single
defect mutant enzymes, which is the better representation of
TABLE I
Kinetics of wild type and mutant B. subtilis adenylosuccinate lyases
The activities were measured from the decrease in absorbance at 282 nm using SAMP in 50 mM HEPES, pH 7, at 25 °C. The Km values were
calculated by varying the SAMP concentration from 5 to 150 M, and the Vmax was determined by extrapolation to saturating concentrations of
substrate.
Enzyme Vmax kcat Km kcat/Km
mol min1 mg1 s1 M M 1 s1
1. Wild type 1.87  0.04 1.57  0.03 4.0  0.7 3.90  105
2. I62E 0.08  0.003 0.07  0.003 17.5  2.8 0.03  105
3. I62D 0.03  0.009 0.03  0.008 55.1  10 0.005  105
4. D69E 0.41  0.009 0.34  0.008 1.3  0.6 2.64  105
5. I62E/D69E 0.10  0.002 0.08  0.002 4.3  0.8 0.19  105
6. I62D/D69E 0.03  0.001 0.03  0.001 17.7  2.2 0.01  105
7. D65R 1.27  0.007 1.07  0.006 4.6  1.4 2.31  105
8. D65R/D69E 0.24  0.01 0.20  0.008 2.0  0.4 1.00  105
9. I62E/D65R a 0.57  0.004 0.48  0.003 18.1  2.4 0.26  105
10. I62E/D65R/D69Eb 0.27  0.01 0.23  0.008 6.1  1.3 0.37  105
11. I62D/D65Rc 0.06  0.002 0.05  0.002 48.8  9.7 0.01  105
12. I62D/D65R/D69Ed 0.07  0.005 0.06  0.004 10.7  2.4 0.05  105
a Humanized normal B. subtilis enzyme.
b 69 mutant (mimics human defect at 87).
c 62 mutant (mimics human defect at 80).
d Double defect.
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the affected individual, has a 2-fold higher Vmax than the dou-
ble defect enzyme. Also, the lowered Vmax values of I62E and
I62D mutant enzymes suggest that Asp65 in the B. subtilis
causes an unfavorable interaction with the negatively charged
residues at 62 in I62E and I62D. Therefore, it was important to
change Asp to Arg at position 65 to mimic the human enzyme.
The normal human-like enzyme has a 4-fold higher Km than
wild type B. subtilis, but the X62D mutation causes about a
14-fold increase in Km. The catalytic efficiency of the human
like X62D mutant enzyme is 25-fold less than the normal
human like enzyme. Therefore, the mutation at position 62,
which corresponds to human mutation E80D, is more deleteri-
ous than the mutation at position 69, which corresponds to
human mutation D87E.
TABLE II
Comparison of adenylosuccinate and SAICAR activities of wild type and mutant enzymes
The enzyme activity for the two substrates were each measured using 90 M substrate in 50 mM HEPES, pH 7, at 25 °C.
Enzyme SAMP SAICAR SAICAR/SAMP
mol min1 mg1 mol min1 mg1
Wild type 1.58 1.70 1.07
I62E/D65R 0.54 0.53 0.97
I62E/D65R/D69E 0.33 0.46 1.40
I62D/D65R 0.063 0.069 1.09
I62D/D65R/D69E 0.072 0.094 1.30
I62D/D65R  I62E/D65R/D69E 0.18 0.24 1.29
FIG. 4. Circular dichroism spectra
of wild type and mutant enzymes.
These spectra were determined with each
protein (0.25 mg/ml) in 20 mM potas-
sium phosphate buffer, pH 7, containing
20 mM sodium chloride. A, single-point
mutations. B, human-like mutations. (C)
Control mutations.
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Based on the crystal structure of the T. maritima enzyme,
homology models of the mutant enzymes were constructed in
the B. subtilis enzyme. The energy minimized models of the
wild type and mutant enzymes are superimposable, indicating
no major conformational changes have taken place in the back-
bone structure of the enzymes. But there are some notable local
changes, which are shown in Fig. 6. The normal human-like
enzyme model is shown in Fig. 6A. The mutant enzymes with a
single defect at position 62 or 69 are shown in Fig. 6B and Fig.
6C, respectively. Previous studies have shown protonated His68
to be a critical active site residue (14), which promotes the
elimination reaction by acting as a general acid and also facil-
itates SAMP binding by interacting with the two carboxylates
of its succinyl moiety. We propose that Asp69 must interact
with His68 to raise its pK and keep it in its protonated state.
Mutations at 62 and 69 indirectly change the distances be-
tween the active site residue His68 and the -COO– and
-COO– of SAMP, as well as between Asp69 and His68. This
distortion of the enzyme-substrate complex may cause the low
activity and binding seen in these mutant enzymes.
In the I62D/D65R model (Fig. 6B), Lys260 from the adjoining
subunit is only 3.03 Å from X62D compared with 5.55 Å in the
normal human-like enzyme with an Glu at position 62 (Fig.
6A). This intersubunit perturbation indirectly increases the
distance between Asp69 and His68 and changes the relative
distances between His68 and the two succinyl carboxylates.
This perturbation of the subunit interactions may cause the
instability of this mutant enzyme. In the I62E/D65R/D69E
model (Fig. 6C), the 69 to 68 distance is closer to that of the
normal human-like enzyme, but the relative proximity of the
His68 and the two succinyl carboxylates is still altered (one
TABLE IV
Thermal inactivation of wild type and ASL-deficient mutant enzymes
Enzymes were incubated at 37 °C, and time-dependent loss in activ-
ity was measured at 25 °C with 60 M adenylosuccinate in 50 mM
HEPES at pH 7 over the time period shown in Fig. 5.
Enzyme k
103 min1
Wild type 3.3  0.4
I62E/D65R 9.2  0.3
I62E/D65R/D69E 0.2  0.5
I62D/D65R 25.0  1.0
I62D/D65R/D69E 12.0  0.3
I62D/D65R  I62E/D65R/D69E 5.2  0.3
FIG. 5. Thermal Inactivation of wild type and ASL-deficient
mutant enzymes at 37 °C. The enzyme activities are expressed as
E/Eo (observed activity/initial activity). The following enzymes are
shown: wild type (E), I62E/D65R (●), I62E/D65R/D69E (Œ), I62D/D65R
(‚), I62D/D65R/D69E (), and I62D/D65R  I62E/D65R/D69E ().
The rate constants are summarized in Table IV.
TABLE III
Molecular weights of wild type and ASL-deficient mutant enzymes
Enzyme Molecular weight
Wild typea 181,000  300
I62Ea 173,000  700
I62Da 176,000  200
D69Ea 155,000  1800
I62E/D65R/D69Ea 159,000  700
I62D/D65R/D69Ea 234,000  2500
I62E/D65Rb 209,000
I62D/D65Rb 217,000
a The molecular weights shown were determined by light scattering
at a concentration of 0.25 mg/ml.
b Molecular weights were determined by native gel electrophoresis
along with wild type enzyme. The wild type enzyme had a molecular
weight of 210,000. These two mutant enzymes also exhibited higher
molecular weight.
FIG. 6. Homology models of mutant B. subtilis ASL. A, I62E/
D65R: normal human-like mutant enzyme. B, I62D/D65R: single defect
at 62 (corresponding to human mutation E80D). C, I62E/D65R/D69E:
single defect at 69 (corresponding to human mutation D87E). SAMP,
relevant active-site amino acids and mutant residues are colored ac-
cording to the atom and shown in space-form. Subunit residue labels
are colored consistently, subunit I (red) and subunit II (blue), to show
subunit interface interaction.
Two Novel Mutant Human ASLs Associated with Autism 53795
 at UQ Library on M
arch 15, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
distance is greater and the other smaller). This distortion of an
active site residue, His68, and perturbation in the subunit
interactions at Lys260, may be responsible for the ASL defi-
ciency disease seen in this patient.
ASL deficiency has been classified into two types: Type I
exhibits severe disease, whereas Type II has milder clinical
features. In both the levels of S-Ado and SAICA-riboside are
elevated, but in Type I the ratio of S-Ado/SAICA-riboside is
1 and in Type II the ratio is 2 or greater (2). The affected
individual has a S-Ado/SAICA-riboside ratio of 2.4, a value
consistent with mild ASL deficiency. Studies on other ASL
deficiency mutants have shown that in some cases the rela-
tive activity of the enzyme toward the two substrates is
related to the severity of the disease and to the ratio of the
dephosphorylated compounds found (9). However, the results
shown here suggest that this classification system may be an
oversimplification: the mutant enzymes mimicking those of
the proband, have lost activity equally for both substrates.
This result is consistent with the observations reported by
Kmoch et al. (8) in which the mutant enzymes studied dis-
played proportional decrease in activity toward both sub-
strates, yet the individual patients had different concentra-
tion ratios of the dephosphorylated forms of the two
substrates in the cerebrospinal fluid. It may be that a mild
clinical presentation can be accompanied by parallel loss of
enzyme activity. The distinction between Type I and Type II
disease may be more complex than simply the differential
loss of activities with the two substrates. The various ratios
of the dephosphorylated compounds found in biological fluids
could be due to a secondary effect, such as unequal rates of
dephosphorylation or unequal rates of transport of the de-
phosphorylated compounds.
So far, all identified cases of ASL deficiency have an autoso-
mal recessive pattern of inheritance. There have been no ab-
normalities reported for any of the parents of ASL patients, and
the mother of the patient described here appears to be clinically
unaffected. One patient has been reported who carries a 39
base pair deletion of the ASL gene leading to deletion of amino
acids 206–218 in the human sequence (27). The deletion en-
zyme was reported to be inactive (9). Therefore, it appears that
50% of normal ASL activity, as would be present in the parent
of this individual that carries the deletion allele, is sufficient
for normal health and development. An observation consistent
with this interpretation was made by Marie et al., where a
mutation in the ASL promoter of a normal ASL allele coupled
with a missense mutation in the other allele led to severe ASL
deficiency in three ASL deficiency patients (28). The promoter
mutation was found to result in about 33% of normal transcrip-
tion of ASL gene. In this case, the parent of each patient that
carried the promoter mutation on one allele and one normal
allele would have 67% of normal ASL activity. In the present
case, the mother of the patient carries the E80D mutant allele.
The equivalent B. subtilis mutant, I62D/D65R, has about 12%
of normal human-like enzyme activity with either SAMP or
SAICAR. The mother, with the equivalent of one X62D mutant
allele, would be expected to possess well over 50% of normal
ASL activity. This is consistent with the observation that the
mother is clinically unaffected.
The affected individual is heterozygous for the two muta-
tions. Assuming that there is equal expression and stability of
the two mutant enzymes in the proband (unlikely given the
decreased stability of the mutant enzymes), the residual activ-
ity in the proband would be 30%. This is similar to the
residual ASL activity found in many ASL patients (8, 9, 26).
Recent studies on understanding disease-causing mutations
in humans has shown that disease mutations are more likely to
occur at amino acid residues that are highly conserved
throughout evolution (29, 30). In interspecific substitutions, an
Glu to Asp and Asp to Glu change is found to be quite common,
and rarely associated with human genetic diseases. The muta-
tions studied here are not completely consistent with this ob-
servation. The B. subtilis residue Asp69, which corresponds to
human mutation D87E, is completely conserved in different
species, whereas Ile62, which corresponds to human mutation
E80D, is not. Even though the normal amino acid found at
position 80 is not highly conserved, Asp is never found at this
position. One could speculate that this is because a Asp at this
position would inactivate the enzyme and thus be selected
against during evolution. This would be consistent with the
finding that the E80D mutation leads to severe loss of enzyme
activity.
Recently, an individual with a novel, neurologically devas-
tating inborn error of purine biosynthesis caused by a mutation
in AICAR transformylase/IMP cyclohydrolase (ATIC) was de-
scribed by Marie et al. (31). This individual was initially diag-
nosed by the Bratton-Marshall test (32), the most commonly
used diagnostic assay for ASL deficiency, which led to the
identification of massive excretion of AICA-riboside, the de-
phosphorylated counterpart of AICAR, a product of ASL and
substrate for ATIC. AICAR transformylase activity is undetect-
able in this individual, who survived at least until 4 years of
age. Our results and the finding of a mutation in another step
of de novo purine synthesis leading to neurological disease
strongly reinforce the notion that testing for ASL deficiency
(and deficiencies in other steps of de novo purine synthesis)
should be expanded to individuals with developmental delay of
any severity, including individuals with autistic spectrum dis-
order. The Bratton-Marshall test would provide a convenient
initial screen, but would need to be accompanied by additional
methods such as HPLC (2, 6), which is also used in ASL
deficiency, because mutations in steps of the pathway that
cannot be detected by this method can also cause inborn errors
leading to disease.
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